WilmerHale Advises Underwriters in the $692.3 Million Public Offering of Kymera Therapeutics

WilmerHale Advises Underwriters in the $692.3 Million Public Offering of Kymera Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised the underwriters in the public offering of 8,050,000 shares of common stock of Kymera Therapeutics, Inc. (NASDAQ: KYMR), reflecting the full exercise of the underwriters’ option to purchase an additional 1,050,000 shares. Kymera is a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD). Kymera received approximately $692.3 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. 

The WilmerHale team was led by Lisa Firenze and Andrew Langworthy and included Kevin Cheng, Whitley Horning and Amy O’Connell, with assistance from Barish Ozdamar on intellectual property matters and Bruce Manheim on regulatory matters.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel